Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population.

Ashdown HF. et al, (2022), ERJ Open Res, 8

Discordant diagnostic criteria for pneumonia in COPD trials: a review

Wise RA. et al, (2021), European Respiratory Review, 30, 210124 - 210124

Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant.

Turnbull CD. et al, (2021), BMJ Open Respir Res, 8

Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals

Singh D. et al, (2021), International Journal of Chronic Obstructive Pulmonary Disease, Volume 16, 3009 - 3016

Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19

Baker JR. et al, (2021)

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial (vol 398, pg 843, 2021)

Yu L-M. et al, (2021), LANCET, 398, E12 - E12

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.

Yu L-M. et al, (2021), Lancet

Eosinophilic inflammation, coronavirus disease 2019, and asthma: Are inhaled corticosteroids the missing link?

Ramakrishnan S. and Bafadhel M., (2021), Ann Allergy Asthma Immunol, 127

Research priorities for exacerbations of COPD.

Alqahtani JS. et al, (2021), Lancet Respir Med, 9, 824 - 826

Accuracy of the Albus Home Research Device (RD) for the Non-Contact and Passive Monitoring of Nocturnal Respiratory Rate at Home in an Adult Population

Do WI. et al, (2021), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 203

Pediatric Nocturnal Respiratory Rate Monitoring Using a Non-Contact and Passive Bedside Device: Accuracy of the Albus Home Research Device (RD)

Wheeler CJ. et al, (2021), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 203

Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial

RAMAKRISHNAN S. et al, (2021), The Lancet Respiratory Medicine

Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial

Ramakrishnan S. et al, (2021)

Predicting treatment outcomes following an exacerbation of airways disease.

Halner A. et al, (2021), PLoS One, 16

Characterising symptom 'trajectotypes' in patients with COPD

Halner A. et al, (2020), EUROPEAN RESPIRATORY JOURNAL, 56

European expert consensus on assessment and management of hospitalised exacerbations of COPD (CICERO ERS CRC)

Ramakrishnan S. et al, (2020), EUROPEAN RESPIRATORY JOURNAL, 56

Interferon responses are dysfunctional in the epithelium of COPD Patients

Lababidi R. et al, (2020), EUROPEAN RESPIRATORY JOURNAL, 56

Predictive modelling of COPD exacerbation rates using baseline risk factors

Singh D. et al, (2020), EUROPEAN RESPIRATORY JOURNAL, 56

Serum G-CSF is a non-invasive biomarker classifying bacterial/neutrophilic COPD exacerbations

Chakrabarti A. et al, (2020), EUROPEAN RESPIRATORY JOURNAL, 56

A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19: study protocol for the ATOMIC2 trial

HINKS T. et al, (2020), Trials

Load More

Include forthcoming?